2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

@article{Lawitz20102009SA,
  title={2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS},
  author={E. Lawitz and M. Rodriquez-Torres and V. Rustgi and T. Hassanein and M. Rahimy and C. Crowley and J. Freddo and A. Muir and J. McHutchison},
  journal={Journal of Hepatology},
  year={2010},
  volume={52}
}
46 Citations
The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
  • 34
  • Highly Influenced
  • PDF
Update on hepatitis C virus resistance to direct-acting antiviral agents.
  • 174
  • Highly Influenced
  • PDF
Direct-acting antivirals for chronic hepatitis C.
  • 132
  • PDF
Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
  • 69
  • PDF
Chronic hepatitis C: future treatment
  • 72
  • PDF
Interferon-combination strategies for the treatment of chronic hepatitis C.
  • 10
  • PDF
...
1
2
3
4
5
...